Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | The importance of understanding TKI-specific side effects to select the best option for each patient

Valentin Garcia Gutiérrez • 21 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia

Valentin Garcia Gutiérrez, MD, PhD, Hospital Universitario Ramón y Cajal, Madrid, Spain, emphasizes the importance of being aware of the side effects associated with each of the available tyrosine kinase inhibitors (TKIs) in order to select the most appropriate TKI for each patient. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research funding, speaking engagements, ad boards: Novartis, BMS, Incyte, Pfizer

More from Valentin Garcia Gutiérrez

1:30
Unmet needs in CML: life-threatening toxicities, QoL & dealing with intolerance and resistance
Valentin Garcia Gutiérrez • 21 Oct 2022
2:00
Novel treatment strategies for patients with CML who are intolerant or resistant to available TKIs
Valentin Garcia Gutiérrez • 21 Oct 2022

Related Videos

5:27
Young matched unrelated donors versus older-aged matched sibling donors in alloSCT with PTCy
Karthik Nath • 17 Apr 2024
2:12
AlloSCT for AML with MDS-related features as per the ICC and WHO 2022 classifications
Arnon Nagler • 16 Apr 2024
2:02
Relapse incidence post-alloSCT with PTCy for AML in CR1
Arnon Nagler • 16 Apr 2024
1:35
Outcomes of alloSCT following blinatumomab in children and young adults with R/R B-ALL
Mattia Algeri • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals